We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.44 | 0.35% | 127.38 | 389 | 12:22:41 |
From Apr 2019 to Apr 2024
By Chris Wack
Alkermes PLC said Wednesday it has entered into a clinical trial collaboration and supply agreement with Merck & Co. to evaluate nemvaleukin alfa in combination with Keytruda in comparison with investigator choice chemotherapy in patients with platinum-resistant ovarian cancer.
Under the terms of the agreement, Alkermes is responsible for conducting the Phase 3 study, which is planned to begin in the second half of 2021.
Nemvaleukin is Alkermes's novel investigational engineered interleukin-2 variant for immunotherapy.
Alkermes said nemvaleukin in combination with Keytruda has demonstrated antitumor activity in heavily pre-treated patients with platinum-resistant ovarian cancer in an ongoing study, with durable and deepening responses observed.
Alkermes shares were up 5% to $20.10 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 07, 2021 07:46 ET (11:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
